Patents by Inventor Eva Kriegbaum

Eva Kriegbaum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing benzo[1,2-b;4,5-b?]dithiophene-4,8-dicarboxylic acid or its 2,3-dihydro derivative
    Patent number: 9216994
    Abstract: The invention relates to a process for preparing benzo[1,2-b;4,5-b?]dithiophene-4,8-dicarboxylic acid or its 2,3-dihydro derivative, and to novel products prepared by this process.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: December 22, 2015
    Assignee: Merck Patent GmbH
    Inventor: Eva Kriegbaum
  • PROCESS FOR PREPARING BENZO[1,2-B;4,5-B']DITHIOPHENE-4,8-DICARBOXYLIC ACID OR ITS 2,3-DIHYDRO DERIVATIVE
    Publication number: 20150051409
    Abstract: The invention relates to a process for preparing benzo[1,2-b;4,5-b?]dithiophene-4,8-dicarboxylic acid or its 2,3-dihydro derivative, and to novel products prepared by this process.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventor: Eva Kriegbaum
  • Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
    Patent number: 8586599
    Abstract: The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Eva Kriegbaum, Frank Stieber, Cristina Donini
  • Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof
    Publication number: 20110257180
    Abstract: The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Application
    Filed: November 24, 2009
    Publication date: October 20, 2011
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Eva Kriegbaum, Frank Stieber, Cristina Donini